Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection.

Marzinke MA, Clarke W, Wang L, Cummings V, Liu TY, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S, del Rio C, Magnus M, Mannheimer S, Fields SD, Mayer KH, Wheeler DP, Koblin BA, Eshleman SH, Fogel JM.

Clin Infect Dis. 2014 Jan;58(1):117-20. doi: 10.1093/cid/cit672. Epub 2013 Oct 2.


Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009.

Savage EJ, Lowndes CM, Sullivan AK, Back DJ, Else LJ, Murphy G, Gill ON.

AIDS. 2016 Jan 2;30(1):145-9. doi: 10.1097/QAD.0000000000000868.


Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

Chen I, Clarke W, Ou SS, Marzinke MA, Breaud A, Emel LM, Wang J, Hughes JP, Richardson P, Haley DF, Lucas J, Rompalo A, Justman JE, Hodder SL, Eshleman SH.

PLoS One. 2015 Oct 7;10(10):e0140074. doi: 10.1371/journal.pone.0140074. eCollection 2015.


Syphilis among men who have sex with men (MSM) in Taiwan: its association with HIV prevalence, awareness of HIV status, and use of antiretroviral therapy.

Huang YF, Nelson KE, Lin YT, Yang CH, Chang FY, Lew-Ting CY.

AIDS Behav. 2013 May;17(4):1406-14. doi: 10.1007/s10461-012-0405-9.


Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A, Bonora S.

Clin Infect Dis. 2015 Jan 15;60(2):311-7. doi: 10.1093/cid/ciu773. Epub 2014 Oct 3.


The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum.

Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S; Japanese HIV-MDR Study Group.

Jpn J Infect Dis. 2017 Mar 24;70(2):158-160. doi: 10.7883/yoken.JJID.2015.599. Epub 2016 Jun 30.


Differences in human immunodeficiency virus care and treatment among subpopulations in the United States.

Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, Gray KM, Cohen SM, Mermin J, Skarbinski J.

JAMA Intern Med. 2013 Jul 22;173(14):1337-44. doi: 10.1001/jamainternmed.2013.6841.


Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.

Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, Heffelfinger JD.

MMWR Surveill Summ. 2011 Sep 2;60(11):1-20.


Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.

Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibáñez L, Rodríguez C, Casadellà M, Santos JR, Ruiz L, Clotet B, Paredes R.

Clin Infect Dis. 2014 Aug 15;59(4):578-88. doi: 10.1093/cid/ciu287. Epub 2014 May 29.


Engagement in HIV care among HIV-positive men who have sex with men from 21 cities in the United States.

Paz-Bailey G, Pham H, Oster AM, Lansky A, Bingham T, Wiegand RE, Dinenno E, Skarbinski J, Heffelfinger JD.

AIDS Behav. 2014 Apr;18 Suppl 3:348-58. doi: 10.1007/s10461-013-0605-y.


Gender and access to HIV testing and antiretroviral treatments in Thailand: why do women have more and earlier access?

Le Coeur S, Collins IJ, Pannetier J, Lelièvre E.

Soc Sci Med. 2009 Sep;69(6):846-53. doi: 10.1016/j.socscimed.2009.05.042. Epub 2009 Jul 1.


Primary antiretroviral drug resistance in newly human immunodeficiency virus-diagnosed individuals testing anonymously and confidentially.

Markovitz AR, Thibault CS, Brandauer PW, Buskin SE.

Microb Drug Resist. 2011 Jun;17(2):283-9. doi: 10.1089/mdr.2010.0066. Epub 2011 Mar 7.


Factors Associated with Immunological Discordance in HIV-Infected Patients Receiving Antiretroviral Therapy with Complete Viral Suppression in a Resource-Limited Setting.

Mingbunjerdsuk P, Asdamongkol N, Sungkanuparph S.

Jpn J Infect Dis. 2015;68(4):301-4. doi: 10.7883/yoken.JJID.2014.062. Epub 2015 Feb 13.


A Cross-Sectional Survey of HIV Testing and Prevalence in Twelve Brazilian Correctional Facilities.

Sgarbi RV, Carbone Ada S, Paião DS, Lemos EF, Simionatto S, Puga MA, Motta-Castro AR, Pompilio MA, Urrego J, Ko AI, Andrews JR, Croda J.

PLoS One. 2015 Oct 14;10(10):e0139487. doi: 10.1371/journal.pone.0139487. eCollection 2015.


Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.

Bakeera-Kitaka S, Conesa-Botella A, Dhabangi A, Maganda A, Kekitiinwa A, Colebunders R, Boulware DR.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1082-6. doi: 10.5588/ijtld.10.0538.


Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection in Seoul, South Korea.

Kim SB, Kim HW, Kim HS, Ann HW, Kim JK, Choi H, Kim MH, Song JE, Ahn JY, Ku NS, Oh DH, Kim YC, Jeong SJ, Han SH, Kim JM, Smith DM, Choi JY.

Scand J Infect Dis. 2014 Feb;46(2):136-40. doi: 10.3109/00365548.2013.851415. Epub 2013 Nov 15.


Management of human immunodeficiency virus in primary care.

Sell JK.

Prim Care. 2013 Sep;40(3):589-617. doi: 10.1016/j.pop.2013.05.002. Epub 2013 Jul 24. Review.


Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC.

Clin Infect Dis. 2005 Dec 15;41(12):1787-93. Epub 2005 Nov 10.


Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.

N Engl J Med. 2006 Sep 14;355(11):1141-53.

Supplemental Content

Support Center